Overview

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Status:
Completed
Trial end date:
2007-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the efficacy of three drugs (cyproterone acetate, medroxyprogesterone acetate and venlafaxine) in the treatment of hot flushes caused by leuprorelin LP 11.25 milligram (mg) in participants suffering from prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Treatments:
Cyproterone
Cyproterone Acetate
Flutamide
Leuprolide
Medroxyprogesterone
Medroxyprogesterone Acetate
Venlafaxine Hydrochloride